{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:17:19Z","timestamp":1777940239087,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Prog Transpl"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    Due to increased risk of myalgia and rhabdomyolysis associated with the use of simvastatin with cyclosporine, use of high-intensity 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors (statins) is often avoided in transplant recipients.\n                    <jats:bold>Aim:<\/jats:bold>\n                    This program evaluation aimed to determine the safety of high-intensity statins in liver and kidney transplant recipients taking tacrolimus.\n                    <jats:bold>Design:<\/jats:bold>\n                    All liver and kidney transplant recipients who filled prescriptions for tacrolimus and any statin except for simvastatin between June 15, 2020 and July 22, 2022 were screened for inclusion. High-intensity was defined as atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg. The primary outcome was a composite of statin-related myalgia, statin-related rhabdomyolysis, and creatine kinase above the upper limit of normal. Secondary outcomes included liver function tests above 3 times the upper limit of normal, statin discontinuation, and statin dose decrease and associated reason.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 178 recipients were included, with 100 receiving low-to-moderate-intensity statins and 78 receiving high-intensity statins. There were no differences between groups for statin-related myalgia, and no reported cases of statin-related rhabdomyolysis in either group. Low to moderate intensity statin use was associated with an increased rate of liver function test elevation (26% vs 11.5%,\n                    <jats:italic>P<\/jats:italic>\n                    = .014) occurring a median of 306 days (interquartile range [IQR] 134\u2013725) post-statin initiation.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In liver and kidney transplant recipients receiving tacrolimus, the use of high-intensity statins was not associated with an increased risk of myalgia, rhabdomyolysis, or elevated creatinine kinase when compared with low-to-moderate-intensity statin use.\n                  <\/jats:p>","DOI":"10.1177\/15269248251349768","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:46:31Z","timestamp":1751017591000},"page":"178-182","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of Concomitant Use of Tacrolimus and High-Intensity Statins in Liver and Kidney Transplant Recipients"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-9108","authenticated-orcid":false,"given":"Kelsey","family":"Klein","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, University of Texas at Austin, College of Pharmac, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Klimatcheva","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, University of Texas at Austin, College of Pharmac, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed","family":"Hall","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, University of Texas at Austin, College of Pharmac, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupal","family":"Patel","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kermit V.","family":"Speeg","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Guerrero","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-5923","authenticated-orcid":false,"given":"Christina","family":"Long","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, University Health, University Health System, San Antonio, TX, USA"},{"name":"University of the Incarnate Word, Feik School of Pharmacy, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144080"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05081107"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13454"},{"key":"e_1_3_3_5_2","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: new restrictions contraindications and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011; Accessed May 6 2025 https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor Accessed May 6 2025."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23950"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000456"},{"key":"e_1_3_3_8_2","article-title":"KDIGO Clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9(Suppl):S1-S155. doi:https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x","journal-title":"Am J Transplant"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01005.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000124"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000112"}],"container-title":["Progress in Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15269248251349768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15269248251349768","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15269248251349768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:42:35Z","timestamp":1777700555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15269248251349768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/15269248251349768"],"URL":"https:\/\/doi.org\/10.1177\/15269248251349768","relation":{},"ISSN":["1526-9248","2164-6708"],"issn-type":[{"value":"1526-9248","type":"print"},{"value":"2164-6708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}